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EDITORIAL
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This editorial refers to ‘Validation of the AF-QoL, a
disease-specific quality of life questionnaire for patients
with atrial fibrillation’ by F. Arribas et al., on page 364.
Atrial fibrillation (AF) is the most common heart rhythm
disorder,1 associated with increased risk of morbidity, mortality,
hospitalization, poor quality of life (QoL), and increased
health care utilization.2 Atrial fibrillation is considered to be a
growing epidemic, with the rise in the prevalence of AF primarily
attributed to the aging population and improved treatment
options for coronary artery disease, heart failure, and hyperten-
sion, leading, in turn, to improved survival in these subsets of
patients.
In the treatment of cardiovascular disease, there is an increasing
recognition that it is important to assess the impact of disease on
patients’ daily functioning and QoL, thereby representing the
patient’s perspective.3 Patient-reported health status and QoL
have been shown to predict mortality, independently of traditional
biomedical risk factors both in coronary artery-disease and heart
failure.4 No such data are as yet available in patients with AF.
However, given that there seems to be little overlap between indi-
cators of AF disease severity and QoL,5,6 poor QoL may also likely
be independently associated with prognosis in patients with AF.
Moreover, subgroups of patients with heart disease indicate that
they prefer symptom improvement and well-being over prolonged
survival.7 As such, treatments for AF should also be evaluated
with respect to their influence on QoL and general well-being.
Unfortunately, QoL is not commonly assessed in clinical cardiology
practice today, nor it is possible to derive a proxy measure for
QoL based on factors assessed routinely. Hence, patient-rated
QoL deserves to be studied in its own right, also because it
may provide information about the most appropriate
treatment, and be used as a performance measure by which to
evaluate the effects of treatment and judge the quality of care
given to patients.3
A range of generic measures for assessment of QoL are avail-
able, including the Short Form Health Survey (SF) 12 or 36, that
are frequently used in patients with somatic disease. However,
generic measures do not tap symptoms pertinent to patients,
and may therefore be less sensitive to capture changes in QoL
over time when compared with disease-specific measures. In con-
trast, few validated and standardized disease-specific instruments
exist that tap AF-specific symptoms, with current measures
having some shortcomings.8
Arribas et al.9 present the results on the AF-QoL-18, an 18-item
disease-specific measure developed to assess QoL in patients with
AF. The development of AF-QoL-18, from item generation to item
selection and reduction in the number of items, has previously
been described.10 In this paper, the authors provide important
additional information on the instrument, subjecting it to a rigor-
ous examination with respect to its psychometric properties.
Their results confirm and further elaborate the instrument’s discri-
minating validity with respect to its ability to distinguish between
patients who present with AF-related symptoms vs. no symptoms,
and its reliability in terms of a good internal consistency (Cron-
bach’s alpha of 0.92 for the total scale and levels higher than
0.80 for the subdomains) and test–retest reliability.9 Importantly,
the authors also examined and established that the instrument is
sensitive enough to capture changes in AF symptoms over time.
The latter finding is important, as it indicates that the
AF-QoL-18 is suitable to use as an outcome measure in clinical
trials and observational studies, but also that it is appropriate to
use as a performance measure in clinical practice to evaluate the
influence of treatment and medical care.
With its 18 items, the AF-QoL-18 comprises little burden to
patients and to clinical practice when compared with generic
measures such as the SF-36. An additional advantage of the
AF-QoL-18 is that it is a multi-dimensional measure, capturing
three QoL domains of psychological, physical, and sexual activity.
The psychological domain taps depression and cardiac anxiety;
the physical domain fatigue and vitality; and the sexual domain
sexual activity and fear of being sexually active. Although the cross-
cultural validity of the measure still needs to be established, the
preliminary data on the AF-QoL-18 look promising in terms of
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filling the gap in the armamentarium of instruments that we have
available for the assessment of QoL in AF patients.
In conclusion, time has come to consider including a QoL
measure, such as the AF-QoL-18, as part of standard assessments
in clinical practice, in order to evaluate the impact of AF on
patients. This information is likely to provide additional value to
the current standard assessments, and may help evaluate the
standard of care given to patients in order to determine
whether their treatment needs to be optimized.3 The AF-
QoL-18 may also be used as a primary outcome in trials
because of its sensitivity to tap change, if a reduction in AF symp-
toms and improvement of QoL are the intended outcome. More-
over, the measure could be used in combination with other
outcomes, because the use of multiple outcomes is likely to
better capture the complexity of AF and disease burden to
patients.11 One potential caveat to bear in mind when using a
QoL measure in AF is that AF recurrences in symptomatic
patients may not all be attributable to AF but to other disease-
causing processes.11
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